Welcome to CDC stacks | Letter: hepatitis B surface seroclearance does reduce the risk of hepatocellular carcinoma - authors’ reply - 42169 | CDC Public Access
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Letter: hepatitis B surface seroclearance does reduce the risk of hepatocellular carcinoma - authors’ reply
Filetype[PDF-30.37 KB]


No Related Documents.
You May Also Like:
  1. Nested Case-Control Study: Hepatocellular Carcinoma Risk After Hepatitis B Surface Antigen Seroclearance
    Personal Author:
    Gounder, Prabhu P.; Bulkow, Lisa R.; Snowball, Mary; Negus, Susan; Spradling, Philip R.; Simons, Brenna C.; McMahon, Brian J.;
    Published:
    Apr 08 2016
    Source:
    Aliment Pharmacol Ther. 43(11):1197-1207.
    Description:
    Background : Hepatocellular carcinoma (HCC) risk after resolving chronic hepatitis B virus (HBV) infection is unclear. : Aim : To compare HCC risk between Alaska Native (AN) patients with and without hepatitis B surface antigen (HBsAg) seroclearance....
    File Type:
    Filetype[PDF - 374.54 KB]
  2. Rates and risk factors for hepatitis B reactivation in a cohort of persons in the inactive phase of chronic hepatitis B—Alaska, 2001–2010
    Personal Author:
    Tohme, Rania A.; Bulkow, Lisa; Homan, Chriss E.; Negus, Susan; McMahon, Brian J.;
    Published:
    Aug 16 2013
    Source:
    J Clin Virol. 58(2):396-400.
    Description:
    Background : A high prevalence of reactivation of hepatitis B has been documented among immunosuppressed individuals in the inactive phase of chronic hepatitis B; However, the proportion of and the risk factors for reactivation are largely unknown am...
    File Type:
    Filetype[PDF - 295.52 KB]
  3. Population-Based Longitudinal Study of Hepatitis B “e” Antigen Negative persons with Chronic Hepatitis B: Level of HBV DNA and Liver Disease
    Personal Author:
    McMahon, Brian J; Bulkow, Lisa; Simons, Brenna; Zhang, Yuhong; Negus, Susan; Homan, Chriss; Spradling, Philip; Teshale, Eyasu; Lau, Daryl; Snowball, Mary; Livingston, Stephen;
    Published:
    Sep 11 2013
    Source:
    Clin Gastroenterol Hepatol. 12(4):701-6.e1-3.
    Description:
    Conclusion : Of participants, 26% met criteria for immune active HBV. An HBV DNA level of > 20,000 IU/ml was strongly correlated with persons meeting the current guidelines for antiviral therapy.
    File Type:
    Filetype[PDF - 285.37 KB]
  4. Cost-effectiveness analysis of hepatocellular carcinoma screening by combinations of ultrasound and alpha-fetoprotein among Alaska Native people, 1983–2012
    Personal Author:
    Gounder, Prabhu P.; Bulkow, Lisa R.; Meltzer, Martin I.; Bruce, Michael G.; Hennessy, Thomas W.; Snowball, Mary; Spradling, Philip R.; Adhikari, Bishwa B.; McMahon, Brian J.;
    Published:
    May 18 2016
    Source:
    Int J Circumpolar Health. 2016; 75.
    Description:
    Background : The American Association for the Study of Liver Diseases (AASLD) recommends semi-annual hepatocellular carcinoma (HCC) screening using ultrasound (US) in persons with chronic hepatitis B (CHB) virus infection at high risk for HCC such as...
    File Type:
    Filetype[PDF - 356.71 KB]
  5. Preventing hepatitis B in people in close contact with hepatocellular carcinoma patients.
    Personal Author:
    Oberle, M W; Shapiro, C N; Lanier, A P;
    Published:
    1997 Jan-Feb
    Source:
    Public Health Rep. 112(1):63-65
    Description:
    To determine the prevalence of testing for hepatitis B virus (HBV) infection in the clinical management of primary liver cancer (hepatocellular carcinoma).|The authors reviewed the records of 78 patients treated for hepatocellular carcinoma in hospit...
    File Type:
    Filetype[PDF - 688.81 KB]